MarketCap
Facebook
X
Telegram
Ovid Therapeutics General and Administrative Expenses | OVID
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Ovid Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.1 M | 25.7 M | 31.1 M | 32.4 M | 37.2 M | 30.6 M | 19.3 M | 19.1 M | 15 M | 13 M | 6.58 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.2 M | 6.58 M | 23.1 M |
Quarterly General and Administrative Expenses Ovid Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.67 M | 6.47 M | 6.66 M | 6.42 M | 6.78 M | 4.88 M | 6.02 M | 4.88 M | 5.54 M | 8.1 M | 7.17 M | 7.69 M | 6.8 M | 8.25 M | 8.34 M | - | 7.63 M | 8.26 M | 9.88 M | 8.26 M | 6.76 M | 6.63 M | 15.6 M | 10.4 M | 7.44 M | 7.11 M | 5.67 M | 5.16 M | 5.17 M | 4.2 M | 4.72 M | - | 4.63 M | 5.09 M | 4.96 M | - | 3.51 M | 4.21 M | 2.98 M | - | 3.12 M | 3.65 M | 2.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.6 M | 2.59 M | 6.37 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
29.7 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
22.1 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
8.74 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
86.2 M | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
26.3 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
12 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
9.48 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
11.5 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
56 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
13.2 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
11.8 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
82.8 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
28.9 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
31.7 M | $ 4.2 | -0.36 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
14 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
3.64 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
3.65 M | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
16.3 M | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
1.04 B | $ 316.97 | 4.77 % | $ 24.7 B | USA |
|
TFF Pharmaceuticals
TFFP
|
10.6 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
7.27 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
87.3 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
15.8 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
284 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
170 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
7.05 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
14.8 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
27.6 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
1.81 B | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
23.7 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
23.6 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
3.14 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
216 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
18.5 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
146 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
24.4 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
36.2 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
11.1 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
13.2 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
8.89 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
191 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |